Trodelvy (sacituzumab govitecan)

Numéro de dossier de l’APP: 21756
État des négociations:
Active Negotiation
Indication(s):
For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease
Promoteur/fabricant:
Gilead Sciences Canada Inc.
Numéro de projet de l’ACMTS:
PC0254
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Not Applicable